Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Earnings for Arcus Biosciences, Inc. (RCUS)
Earnings in 2023 (TTM): $-301,000,000
According to Arcus Biosciences, Inc.'s latest financial reports the company's current earnings (TTM) are $-301,000,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Arcus Biosciences, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-301,000,000 | $-307,000,000 |
| 2022 | $-266,000,000 | $-267,000,000 |
| 2021 | $54.65 M | $53 M |
| 2020 | $-122,858,000 | $-116,677,000 |
| 2019 | $-84,710,000 | $-75,931,000 |
| 2018 | $-49,594,000 | $-49,594,000 |
| 2017 | $-53,082,000 | $-53,082,000 |
| 2016 | $-17,970,000 | $-17,970,000 |